Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06271512 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 5 to 6v6
  2. Study sites: 4 to 5v5
  3. Study sites: 3 to 4v4
  4. Study sites: 2 to 3v3
  5. Study sites: 1 to 2v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
Trial Details
NCT Number NCT06271512
Lead Sponsor Genetix Biotherapeutics Inc.
Collaborators: Center for International Blood and Marrow Transplant Research
Conditions
(from sponsor)		 Beta-Thalassemia
Related terms beta-Thalassemia
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov